Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas
Authors' conclusion
NMBR antagonist represents a potential treatment for CD and its effect may be mediated by cyclin E suppression.
Study context
- Population
- Human corticotroph, non-functional and somatotroph adenoma specimens; murine AtT-20 cells; mice with tumor xenografts; 7 patient-derived corticotroph adenoma cell cultures7 patient-derived adenomas
- Comparison
- NMBR antagonist PD168368 vs no treatment
- Outcome
- NMB/NMBR expression and effects of PD168368
Methodological detailsin vitro, in vivo xenograft, patient-derived adenoma cells
- In vitro
- In vivo xenograft
- Patient-derived adenoma cells
Main finding
As reported in the abstract
Patient-derived cells: PD168368 reduced POMC mRNA expression
4 of 7 cases
Patient-derived cells: PD168368 reduced adrenocorticotropic hormone (ACTH) secretion
2 of 5 cases
Original publication
Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas. Pituitary. Published 29 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →